GLP-1 Antagonist Shows Clinically Meaningful Results in Post-Bariatric Hypoglycemia
(MedPage Today) -- NATIONAL HARBOR, Md. -- An investigational first-in-class GLP-1 receptor antagonist significantly reduced hypoglycemic events after bariatric surgery in the phase III LUCIDITY trial. From a baseline mean of 2.39 events per...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.